|
|
|
Monday, July 28, 2014
|
|
7:30 am -
8:30 am
|
|
|
|
|
|
8:30 am -
11:45 am
|
Align the Sales Team with Your Hub to Optimize Your Specialty Pharmacy Channel Strategy |
- Identify nimble hubs and reduce barriers for timely functioning to ensure the best outcomes in terms of prior authorizations, time to fill,
and medication persistence
- Apply a marketing mix to successfully promote your hub to the channel — Physicians and consumers
- Bridge the gap between data aggregation and analysis with proper hub design
- Collect the right data to drive adherence and set up a lexicon of data elements for program consistency
|
|
|
Frank F. Dolan
National Sales Director
Corcept Therapeutics, Inc.
|
|
|
Mark Stephan
Regional Director of Access and Reimbursement, Mid Atlantic
Alkermes
|
|
|
| There is a 15 minute coffee and networking break from 10:00 am – 10:15 am |
|
|
11:45 am -
1:00 pm
|
|
|
|
|
|
1:00 pm -
1:15 pm
|
|
|
1:15 pm -
2:00 pm
|
Future Outlook for Specialty Drug Costs and Utilization for High Risk Populations |
- A review of new and existing ways that payers and PBMs are managing specialty drugs under the medical and pharmacy benefit to include a
discussion on:
- Drug formulary development
- Site of care administration
- Split-fill programs to improve adherence
- Initiatives in development for key therapeutic categories – Oncology, Hepatitis C, RA, and MS
- Maximizing co-pay and patient assistance program effectiveness to increase patient access
|
|
|
Raulo Frear, PharmD
General Manager
OmedaRx
|
|
Bill Goodson
Deputy Director, Pricing, Reimbursement and Patient Assistance
Bayer Healthcare
|
|
|
|
|
2:00 pm -
3:30 pm
|
|
Understand the Contractual, Operational, and Regulatory Nuances of Specialty Pharmacy Contracting |
|
|
Michael R. Hess
Chair-Drug, Device and Life Sciences Industry Service Team
Baker, Donelson, Bearman, Caldwell & Berkowitz, PC
Former Chief Counsel and Vice President, Strategic Development
Accredo Health Group
|
|
Reactor Panel:
Improve Manufacturer and Specialty Pharmacy Contractual Relationships for Rare Disease and Specialty Drugs |
| Moderator: |
|
|
Michael R. Hess
Chair-Drug, Device and Life Sciences Industry Service Team
Baker, Donelson, Bearman, Caldwell & Berkowitz, PC
Former Chief Counsel and Vice President, Strategic Development
Accredo Health Group
|
|
| Panelists: |
|
|
|
|
Wesley Winn, MHS, MBA
Vice President, Commercial Operations, Supply Chain & Market Access
Hyperion Therapeutics
|
|
|
|
|
3:30 pm -
4:00 pm
|
|
|
4:00 pm -
4:45 pm
|
Understand the Complexities of Adherence Measurement by Disease and Specialty Drug Category |
- Understand current and planned specialty pharmacy measure development activities, including strategies to address challenges
- Describe the differences between Medication Possession Ratio (MPR) and Proportion of Days Covered (PDC) and how that impacts adherence
measurement in specialty patient populations
- Discuss key benefits and challenges with applying adherence metrics across specialty drug therapies
|
|
|
|
|
4:45 pm -
5:30 pm
|
Anticipated Impact of Biosimilars on the Specialty Landscape |
- An overview of the key regulatory unknowns associated with biosimilars in the US
- Understand the various perspectives and how stakeholders from manufacturers to physicians to payers will impact biosimilar uptake in the US
- Key lessons from biosimilars outside of the US and successes and the challenges
- Discuss implications for the distribution strategy for branded products
|
|
Molly Burich
Senior Manager, Government Affairs - Reimbursement and Policy
Otsuka Pharmaceuticals
|
|
|
|
|
5:30 pm -
6:30 pm
|
|
|
|
